Search research articles
Contact Us
Filters
Showing results (101-110 of 336) with videos related to
Page
of 34
Sort By:
Cancer Chemotherapy and Pharmacology
|
March 6, 2010
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
Matteo Dalla Chiesa, Gianluca Tomasello, Sebastiano Buti, et al.
Technology in Cancer Research & Treatment
|
March 25, 2025
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma
Michele Maffezzoli, Alessio Signori, Davide Campobasso, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
September 23, 2021
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
Umberto Maggiore, Alessandra Palmisano, Sebastiano Buti, et al.
Current Oncology Reports
|
July 20, 2025
The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?
Michele Maffezzoli, Ria Nagpal, Mohamed Elewaily, et al.
Nature Reviews. Urology
|
January 24, 2024
Pembrolizumab plus enfortumab vedotin in urothelial cancer
Matteo Santoni, Hideki Takeshita, Francesco Massari, et al.
Future Oncology (London, England)
|
February 4, 2021
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
Melissa Bersanelli, Diana Giannarelli, Alessandro Leonetti, et al.
Therapeutic Advances in Medical Oncology
|
November 16, 2020
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
Filippo G Dall'Olio, Francesca Abbati, Francesco Facchinetti, et al.
Future Oncology (London, England)
|
June 18, 2016
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer
Sebastiano Buti, Chiara Ciccarese, Roberto Iacovelli, et al.
International Journal of Cancer
|
December 16, 2025
Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)"
Javier Molina-Cerrillo, Giandomenico Roviello, Ondrej Fiala, et al.
Technology in Cancer Research & Treatment
|
March 1, 2023
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario
Giulia Mazzaschi, Giulia Claire Giudice, Matilde Corianò, et al.
Page
of 34
Search research articles
Search
Showing results (101-110 of 336) with videos related to
Sort By:
Page
of 34
Cancer Chemotherapy and Pharmacology
|
March 6, 2010
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
Matteo Dalla Chiesa, Gianluca Tomasello, Sebastiano Buti, et al.
Technology in Cancer Research & Treatment
|
March 25, 2025
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma
Michele Maffezzoli, Alessio Signori, Davide Campobasso, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
September 23, 2021
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
Umberto Maggiore, Alessandra Palmisano, Sebastiano Buti, et al.
Current Oncology Reports
|
July 20, 2025
The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?
Michele Maffezzoli, Ria Nagpal, Mohamed Elewaily, et al.
Nature Reviews. Urology
|
January 24, 2024
Pembrolizumab plus enfortumab vedotin in urothelial cancer
Matteo Santoni, Hideki Takeshita, Francesco Massari, et al.
Future Oncology (London, England)
|
February 4, 2021
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
Melissa Bersanelli, Diana Giannarelli, Alessandro Leonetti, et al.
Therapeutic Advances in Medical Oncology
|
November 16, 2020
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
Filippo G Dall'Olio, Francesca Abbati, Francesco Facchinetti, et al.
Future Oncology (London, England)
|
June 18, 2016
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer
Sebastiano Buti, Chiara Ciccarese, Roberto Iacovelli, et al.
International Journal of Cancer
|
December 16, 2025
Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)"
Javier Molina-Cerrillo, Giandomenico Roviello, Ondrej Fiala, et al.
Technology in Cancer Research & Treatment
|
March 1, 2023
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario
Giulia Mazzaschi, Giulia Claire Giudice, Matilde Corianò, et al.
Page
of 34